- Home
- MAMA vs MNPR Comparison
MAMA vs MNPR Comparison
Compare MAMA & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAMA
- MNPR
- Stock Information
- Founded
- MAMA 2010
- MNPR 2014
- Country
- MAMA United States
- MNPR United States
- Employees
- MAMA N/A
- MNPR 12
- Industry
- MAMA Specialty Foods
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- MAMA Consumer Staples
- MNPR Health Care
- Exchange
- MAMA Nasdaq
- MNPR Nasdaq
- Market Cap
- MAMA 296.9M
- MNPR 292.9M
- IPO Year
- MAMA N/A
- MNPR 2019
- Fundamental
- Price
- MAMA $7.78
- MNPR $48.50
- Analyst Decision
- MAMA Strong Buy
- MNPR Strong Buy
- Analyst Count
- MAMA 3
- MNPR 4
- Target Price
- MAMA $10.67
- MNPR $43.00
- AVG Volume (30 Days)
- MAMA 315.5K
- MNPR 67.7K
- Earning Date
- MAMA 12-16-2024
- MNPR 03-27-2025
- Dividend Yield
- MAMA N/A
- MNPR N/A
- EPS Growth
- MAMA N/A
- MNPR N/A
- EPS
- MAMA 0.08
- MNPR N/A
- Revenue
- MAMA $116,468,000.00
- MNPR N/A
- Revenue This Year
- MAMA $19.28
- MNPR N/A
- Revenue Next Year
- MAMA $12.74
- MNPR N/A
- P/E Ratio
- MAMA $91.85
- MNPR N/A
- Revenue Growth
- MAMA 17.20
- MNPR N/A
- 52 Week Low
- MAMA $4.23
- MNPR $1.55
- 52 Week High
- MAMA $9.98
- MNPR $49.98
- Technical
- Relative Strength Index (RSI)
- MAMA 46.63
- MNPR 66.31
- Support Level
- MAMA $7.25
- MNPR $34.41
- Resistance Level
- MAMA $8.00
- MNPR $44.86
- Average True Range (ATR)
- MAMA 0.38
- MNPR 5.69
- MACD
- MAMA 0.05
- MNPR 1.13
- Stochastic Oscillator
- MAMA 55.94
- MNPR 91.91
About MAMA Mama's Creations Inc.
Mama`s Creations Inc is a marketer and manufacturer of fresh deli-prepared foods, found in over 8,400 grocery, mass, club, and convenience stores nationally. The company's broad product portfolio, born from a rich history in Italian foods, now consists of a variety of high-quality, fresh, clean, and easy-to-prepare foods to address the needs of both consumers and retailers.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.